#TP53WT - Twitter Hashtag

about 2 years ago · Dallas

Now in print in @gynoncjnls: The results of @GOG #3055, #selinexor maintenance for #TP53wt #endometrialcancer. From @OncLearnNetwork. #gyncsm #clinicaltrial @XPOVIOHCP

Oncology Learning Network @OncLearnNetwork

about 2 years ago

Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer. Learn more: https://t.co/Vr0C5LQWT3 #medtwitter #onctwitter

OncLearnNetwork's tweet photo. Subgroup analysis results from the phase 3 SIENDO study found selinexor demonstrated promising efficacy and safety among patients with advanced or first-line recurrent TP53 wild-type endometrial cancer. Learn more: https://t.co/Vr0C5LQWT3

#medtwitter #onctwitter https://t.co/GAMvq9bhDz

0

3

1

0

1K

0

5

3

0

1K

David Scott Miller @dsmgyo

about 2 years ago · Dallas

Now in print in @gynoncjnls: The results of @GOG #3055, #selinexor maintenance for #TP53wt #endometrialcancer. #gyncsm #clinicaltrial @XPOVIOHCP

@GynOncJnls

@gynoncjnls

about 2 years ago

Long-term follow-up of efficacy and safety of #selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study @SGO_org @IGCSociety @ESGO_society @ASCO https://t.co/DcYXa1KWKJ

gynoncjnls's tweet photo. Long-term follow-up of efficacy and safety of #selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study
@SGO_org @IGCSociety @ESGO_society @ASCO https://t.co/DcYXa1KWKJ https://t.co/f3sBRlShln

0

36

10

3

5K

0

16

6

0

1K

@onc_ce

almost 3 years ago

18c) Most common #TEAEs of any grade were #nausea #vomiting #diarrhea, & most common Grade 3+ were #neutropenia #nausea & #thrombocytopenia. 🔭This work has now advanced to globally enrolling Ph3 ENGOT-EN20, enrolling only pts with #TP53wt #EC after response to initial chemo

1

2

0

1K

@onc_ce

almost 3 years ago

18a) At #ESGO2023, J PérezFidalgo presented this analysis of long-term f/u of #selinexor maintenance in pts with #TP53wt advanced (St 4) or recurrent #EC. After response to #chemo pts are randomized to maintenance selinexor or #placebo.

onc_ce's tweet photo. 18a) At #ESGO2023, J PérezFidalgo presented this analysis of long-term f/u of #selinexor maintenance in pts with #TP53wt advanced (St 4) or recurrent #EC. After response to #chemo pts are randomized to maintenance selinexor or #placebo. https://t.co/JjTGKGEvDj

1

3

0

1K

CrozrX

@CrozrX

almost 5 years ago

https://t.co/TpswuiysHx Focal Adhesion Kinase #FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Squamous Cell Carcinoma #HNSCC in a p53-Dependent Manner #TP53m #TP53Wt #FAKi #sensitizer #RT Hope, @adapthyun @WashURadOnc can expand his clinical study to other cancers

CrozrX's tweet photo. https://t.co/TpswuiysHx
Focal Adhesion Kinase #FAK Drives Resistance to Therapy in HPV-Negative Head and Neck Squamous Cell Carcinoma #HNSCC in a p53-Dependent Manner #TP53m #TP53Wt #FAKi #sensitizer #RT
Hope, @adapthyun @WashURadOnc can expand his clinical study to other cancers https://t.co/XRc2Qoo0Bl

1

8

1

0

Naveen Pemmaraju, MD @doctorpemm

almost 10 years ago

via @NEJM Notable;pts w/AML/MDS: n=116; Decitabine-based tx;signif diff RR b/t pts w/TP53+mutation=21/21[100%]; vs #TP53WT=32/78[41%] #leusm https://t.co/vGzzBq4LLT

NEJM

@NEJM

almost 10 years ago

Original Article: TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes https://t.co/ce8ri2kgus

0

19

29

0

2

0

Top Tweets for #TP53WT

Last Seen Hashtags on Sotwe

Trends for you

Most Popular Users